Avacincaptad Pegol · intravitreal injection
Injections & Implants
Approved uses
Geographic atrophy secondary to age-related macular degeneration
2 mg (0.1 mL of 20 mg/mL) intravitreally into each affected eye once monthly
Slows lesion growth without restoring acuity, and raises the risk of converting to neovascular AMD
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
Single-dose glass vial of 20 mg/mL solution, delivering 2 mg in 0.1 mL.
Avacincaptad pegol is an RNA aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation.
Warnings & Precautions
- Endophthalmitis and Retinal Detachments: Intravitreal injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay.
- Neovascular AMD: In the GATHER1 and GATHER2 clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
- Increase in Intraocular Pressure: Transient increases in intraocular pressure (IOP) have been observed after an intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.
Common Side Effects
The most common adverse reactions (incidence ≥ 5%) were conjunctival hemorrhage, increased IOP, blurred vision, neovascular age-related macular degeneration, punctate keratitis, and eye pain.
Pregnancy: No adequate and well-controlled studies in pregnant women; use may be considered after weighing risks and benefits.
Lactation: There is no information regarding the presence of avacincaptad pegol in human milk, the effects of the drug on the breastfed infant, or the effects of avacincaptad pegol on milk production.
Safety and effectiveness of IZERVAY in pediatric patients have not been established.